CN
CN

CN
Translational Oncology

Translational Oncology

 

  • Biomarker discovery
  • Human tumor bank
  • Mouse clinical trial
  • 67 PDX-derived primary cancer cell lines
  • Drug-resistant PDX models
  • Combination therapy platform including radiation
  • World leading genome sequencing and bioinformatics capability

 

 

In Vitro Pharmacodynamic Capability 

 

  • ELISA (enzyme-linked immunosorbent assay).
  • Western blotting. 
  • Regular PCR and qPCR (real-time quantitative PCR).

 

 

Biomarker Discovery with IHC (immunohistochemistry) 

 

  • Instrument platforms：1）Automated Station/Leica Autostainer XL. 2）Vectra, PerkinElmer (caliper). 3）Fluorescence Microscope/Axio Imager A2 & Nikon NI-U
  • Opal multiplex IHC platform

 

 

DNA FISH Assay

 

  • DNA FISH technique and its clinical application
  • Workflow of DNA FISH
  • HER2, EGFR, and other FISH on FFPE slides
  • DNA FISH on blood sample

 

 

Combination Therapy Platform including Radiation

 

Radiation baseline in syngeneic models 

  • Radiation was recently considered to be promising in combination with immunotherapy, based on its capacity of mobilizing immune responses
  • RadSource RS2000/XE X-ray irradiator suitable for small animal use
  • 2 syngeneic models with radiation therapy data 

 

Radiation baseline in PDX models 

  • 21 PDX models with radiation therapy data

 

Case study: combination therapy with radiation

  • Breast cancer model: BR-05-0028
  • MLN4924, a NAE inhibitor, showed synergetic effect with focal radiation

 

 

PDX Derived Human Cancer Cell Lines (PCC)

 

67 human cancer cell lines generated from PDX models

  • With matched PDX models
  • Cancer stem cell (CSC) features
  • 64/67 form xenografts in mice which recapitulate pathology of the original patient tumor
  • Genomic profiling data available

 

 

Drug-resistant PDX

 

  • Resistance was induced by repeated treatment
  • Genomic profiling data available for erlotinib and crizotinib resistant NSCLC models

 

 

Erlotinib Resistant Lung Cancer PDX Harboring EGFRL858R

 

  • LU-01-0055 PDX harboring EGFRL858R
  • Sensitive to erlotinib
  • Erlotinib resistant LU- 01-0055R
  • Afatinib overcame the erlotinib resistance

 

 

Learn More About Oncology & Immunology

 

 

 

 

Business Contact：